mission possible: rx-360’s vital role wand sales and marketing/membership chair of rx-360, see ....
TRANSCRIPT
InformexUSA 2013 in Review . . . . . . . . . . . . 3SOCMA Expansion Fuels Advocacy Effort . . . 4
Five Minutes With…Jordi Robinson, global head, technical
business development, Navine Flourine International . . . . . . . . . . . . . . . . . . . . . . . . 7
Paul N . Wituschek, VP, global business development, Catalent . . . . . . . . . . . . . . . . 9
John Rice, executive director, The Chemical Education Foundation . . . . 13
Wrap Party Toasts 2013 InformexUSA . . . . . 19
Showcase Snapshots . . . . . . . . . . . . . . . . . . . 20
Exhibitor News . . . . . . . . . . . . . . . . . . . . . . 5–21
Exhibitor Photos . . . . . . . . . . . . . . . . . . . . . . . 22
Advertiser Index . . . . . . . . . . . . . . . . . . . . . . . 21
See To Sell or Not page 18
An all-expert panel debating the issues facing Rx-360 included, from left to right, Tom Beil, VP, quality and regulatory affairs, Sigma / Alrich / SAFC; Kim Cauchy, VP, global sourcing, Mylan;
and William Reis, VP, global strategic sourcing, Amgen
Mission Possible: Rx-360’s Vital Role
What vendor issues keep senior
pharmaceutical procurement professionals
up at night, and how does Rx-360 help
to bridge the gaps between pharmaceutical companies
and their suppliers?
That was the gist of a panel discussion Thursday
designed to illustrate Rx-360’s role in helping to secure
the pharmaceutical supply chain from the perspectives
of corporate and government entities.
Session moderator Scott Watson, executive director
and sales and marketing/membership chair of Rx-360,
See Rx-360 page 18
To Sell or Not—When, Where and How
The value of a business may be much more than
what meets the eye. Business owners have much
to learn from a professional valuation expert
when they decide to sell their businesses. Experts on a
Thursday morning session on “Business Valuation and
the Exit Planning and Sale of Business Process”
Allen Oppenheimer, president of O.M. Oppenheimer,
a 30-year-old business brokerage, valuation expert, and
exit planning strategy company, explained that there are
two reasons to get a business evaluation—internal, for
estate planning, and external, for selling the business.
The evaluation is designed to substantiate the intangible
part of the business’s value, to differentiate between the
“book equity” and the total value of the company to
help the seller get paid for it, Oppenheimer said.
INFORMEX Post Show Daily | FEBRUARY 2013 | Anaheim Convention Center Anaheim California 3
The 29th annual Informex concluded last week with a highly motivated
and qualified audience spending four days in Anaheim immersed in
discovering the latest innovations, trends, and services for the global
chemical marketplace. With 89 percent of the attendees being able to authorize
or recommend purchases, there were thousands of meetings taking place and
partnerships being forged to further the product development and contract
manufacturing plans of the Informex audience.
Other key highlights for this event included: n Top fine chemical product development teams in attendance from the
pharmaceutical and bio technology sectored included: Abbvie, Allergan, Amgen,
Eli Lilly, Gilead, Mylan, Pfizer, Roche, Sanofi, and Sigma-Aldrich.
n Specialty chemicals were being sourced by top executives from AkzoNobel,
Cargill, Dow Argosciences, Dupont, Eastman, ExxonMobil, Honeywell,
Huntsman, Lubrizol, Shell, and Sherwin-Williams
Being in Anaheim, Informex attracted new attendees to this sourcing and
business event, with 32 percent of the audience being first time attendees. This
edition of Informex also had international visitors drawing 34 percent of the
attendees from outside the U.S.
Informex offered more educational programming this year designed to help
attendees with their sourcing and project plans. Sessions of high interest included
Perspectives on the Specialty Chemicals Market; Attn Suppliers: What Keeps
Me Up at Night—How Rx-360 Helps Me Sleep Better; President’s panel on “API
Manufacturing in U.S. is Dead or is it?; and Non-cGMP Manufacturing: What I Look
for in a Toller.
The numerous networking events—hallmarks of Informex— were well attended
and many attendees leveraged these opportunities to strengthen their business
relationships and partnerships.
“We met with many of the Informex advisory board members and key customers
at this year’s Informex and have a renewed sense of purpose and commitment to
developing an even higher quality event for our 30th anniversary in Miami,” said
Daniel Read, portfolio director, UBM Live, the owners and organizer of Informex.
“Their insight, as well as on-going discussions and intelligence gathering with all
sectors of the business, will help us continue to best serve the industry and develop
important platforms that connect the industry in unique and valuable ways.”
Informex 2014 will take place Jan. 21-24, 2014 at the Miami Beach Convention
Center in Miami, FL.
Visit informex.com for more information on all of the brand’s offerings.
Publisher Kenneth M. CarrollEditor Sharon Donovan
Reporter Ilene SchneiderArt Director Connie HameediPhotographers Peter Cutts
Advertising Sales USA Dean Baldwin, Robert LaPointe,
Thomas Scanlan
Europe Uwe Riemeyer, Paul Barrett, Nadia Liefsoens
Asia Minghua Lu, Angel Zu, Mai Hashikura, Shigamaro Yatsui,
Faredoon Kuka
Production Manager Joseph Davis
ACS Publications Advertising Sales Group
480 East Swedesford Road Wayne, PA 19087
Phone 610.964.8061/Fax 610.964.8071
http://cen.acs.org/onsite.html
P u b l i s h e d b y A m e r i c a n C h e m i c a l S o c i e t y
Meetings, Sourcing, Education Top Agenda at InformEx Strong Purchasing Power Of Attendees
Left to right, Michael Feighery, sales manager, InformEx, and Daniel Read, portfolio director, UBM Live, owners and organizers of InformEx
4 INFORMEX Post Show Daily | FEBRUARY 2013 | Anaheim Convention Center Anaheim California
Market Expansion, Competitiveness Highlight SOCMA’s 2013 Advocacy Efforts
With more than 90 new
members and the 113th
Congress preparing to
tackle key legislative issues in the
coming year, the Society of Chemical
Manufacturers and Affiliates
(SOCMA) kicked off its “First 100
Days” initiative Jan. 20 to educate
Congress about issues important to the
specialty chemical industry.
Specifically, SOCMA plans to
advocate for policies to help American
companies be more competitive and
expand their markets. “The government
can do things that can severely harm
our industry’s competitiveness, such
as overregulation and outdated tax
systems, but it can also help us better
compete by strengthening policies that
make growth and innovation a top
priority,” said Bill Allmond, SOCMA’s VP,
government and public relations.
Throughout the 100 days, SOCMA’s
Government Relations team will visit
new members of Congress on Capitol
Hill, as well as various agencies, to
introduce the organization and share
SOCMA’s position on issues such as
regulatory reform; taxes, including the
R&D tax credit; intellectual property
and confidential business information
protection; trade issues, including the
Miscellaneous Tariff Bill and free trade
agreements; chemical security; and
many others.
SOCMA CONNECT’s 6th Annual
Washington Fly-In, set for April 9-10,
is also included in the First 100 Days
initiative. The Fly-In is an opportunity
for SOCMA members to visit Capitol
Hill and talk face-to-face with members
of Congress and their staff to ensure
that elected officials consider the issues
and challenges facing the specialty
chemical industry when voting on
legislation.
As part of the First 100 Days effort,
SOCMA also plans to assist members
in scheduling site visits at their facilities
with members of Congress and
encourage members to write letters to
elected officials regarding the sector’s
top priorities, among other activities.
Visit SOCMA at Booth 2357.
SOCMA members met on the steps of the U.S. Capitol before discussing issues important to the specialty chemical industry with senators and representatives during SOCMA CONNECT’s annual Washington Fly-In.
Site visits like this one at SOCMA member Nation Ford Chemical will be a part of SOCMA’s First 100 Days initiative. From left, representative Mick Mulvaney, Nation Ford Chemical VP Phillip McCarter, and Nation Ford president Jay Dickson.
INFORMEX Post Show Daily | FEBRUARY 2013 | Anaheim Convention Center Anaheim California 5
AFC Production Capacity Increases 30 PercentAMPAC Fine Chemicals (AFC) manufactures active pharmaceutical ingredients
(APIs) and registered intermediates for customers in the pharmaceutical industry.
Its integrated facilities are located in Rancho Cordova, CA, approximately 20
miles east of downtown Sacramento, and in La Porte, TX, approximately 28
miles east of Houston.
With more than 50 years of experience in mastering challenging chemistries,
AMPAC has developed capabilities that support processes and technologies.
Its products are manufactured in compliance with the U.S. Food and Drug
Administration’s current Good Manufacturing Practices.
AFC is a wholly owned subsidiary of American Pacific (AMPAC), a company
with divisions that also manufacture specialty chemicals used in aerospace
and national defense programs, fire protection, water treatment, and other
commercial applications.
With the La Porte expansion, AFC’s total production capacity has been
increased approximately 30 percent, or up to approximately 256m3 (68,000
gallons), with reactors from 20 to 16,000 L (5 to 4,000 gallons).
AFC’s California facility includes four Class 100,000-rated buildings.
Highlights include two commercial-scale continuous simulated moving bed
(SMB) units, a Class 100,000 solids handling and drying facility, three self-
contained, high-containment facilities, remote facilities for conducting hazardous
operations, including a semi-continuous diazomethane system and three
production facilities with azide processing capability.
Visit AMPAC at ww.ampacfinechemicals.com.
Making Products More Durable With Chemtura ChemistryChemtura, a global specialty chemicals company, builds the chemistry that makes
other products more durable, safer, cleaner and more efficient. Major industries
served include transportation, energy and electronics, and agriculture.
With global headquarters in Philadelphia, it manufactures products in 14
countries and sells products in more than 100 countries. With approximately 4,300
employees in research, manufacturing, sales, and administrative facilities in markets
of the world, it operates regional headquarters and shared service centers in the
U.S., Brazil, China, the U.K., and Switzerland.
Among its global initiatives:
n One of the two largest global marketers and sellers of recreational water
products used in pools and spas (Consumer Products)
n A leading niche developer and manufacturer of seed treatments, fungicides,
miticides, insecticides, growth regulants, and herbicides
n One of the three largest developers and manufacturers of bromine and bromine-
based products (Great Lakes Solutions); and of organometallic compounds, that
have applications in catalysts, surface treatment, and pharmaceuticals
It is a global manufacturer and marketer of: high-performance additive components,
building blocks for synthetic lubricant base-stocks; calcium sulfonate specialty greases
and phosphate and polyol ester-based fluids; and hot cast elastomers. The hallmarks of
its businesses include differentiation through technology, investing in sustainable tech-
nologies and applications, increased exposure to higher-growth regions, an expanded
global footprint and infrastructure, greater customer focus and intimacy, and stewardship
of its products and their use. Visit Chemtura at www.chemtura.com.
6 INFORMEX Post Show Daily | FEBRUARY 2013 | Anaheim Convention Center Anaheim California
Contract Research Organization Has More than 200 PatentsAn international and independent group and a custom synthesis supplier, Fabbrica
Italiana Sintetici (FIS) Group is committed to developing, producing, and
delivering active ingredients, key intermediates, advanced intermediates, and
building blocks for the pharmaceutical industry.
With more than 50 years of experience, FIS Group offers an integrated service
to end-users from R&D to full scale production and from grams to tons; a diversifed
team for multiple needs; financial resources to invest for specific projects; and a
personalized, efficient approach for every customer.
As a private Italian contract research organization that specializes in active
pharmaceutical ingredients (API) production, custom synthesis is its core business for
pharmaceutical companies under confidentiality agreements. FIS has the capability to
provide integrated services to the customer, including process research and development,
optimization, and scale-up facilities to support both validation and commercial launch.
With two production plants in Italy and three offices abroad, FIS develops and sells
numerous generic APIs including anxiolytics, anticonvulsants, antidepressants, analgesics,
anti- inflammatory agents, antibacterials, antifungals, cardiovascular drugs, and diuretics.
Fifty-five different APIs are currently produced, combining both generic APIs and
patent protected APIs. The company has the expertise and resources to internally
manage all quality and compliance and regulatory affairs activities required for
custom and generic products.
Since 1960, FIS has filed more than 200 patent applications, primarily directed
at process innovation. Since 2007, FIS has adopted a more rigorous policy of
protection and enforcement of Intellectual Property Rights, increasing the number of
patent applications filed.
Visit Fabbrica Italiana Sintetici (FIS) Group at www.fisvi.com.
CML Invests to Support Late-Phase and Commercial API Demand in PharmaWith sluggishness in the pre-clinical pipelines the past few years, most companies
in the pre-clinical toxicology space have been through numerous quarterly reports
articulating the woes of the past quarter, and the optimism that the future brings.
What has been overlooked until recently is the strength of the late phase
pipelines. Funding has been robust to emerging and mid-sized pharma
companies that have compounds at, or past, phase 2 clinical trials.
Many contract API suppliers who have a strong base of assets to handle
programs from phase 2 through launch have seen growth in their portfolio of
API projects. And Cambridge Major Labs is no exception. In July 2012, CML
embarked on a major expansion of its large scale API plant in Wisconsin.
Scheduled to be complete in April, the expansion will increase CML’s large
scale capacity by nearly 30 percent, enabling more capacity for the large number
of phase 2 and phase 3 APIs in CML’s funnel. Having a supplier that can meet
the growing volume needs as APIs progress to commercialization is key to a
successful new product launch; no technical transfer is required, and the API
supply is effectively de-risked.
Over the next few years, once the clinical pipelines run their course, pre-clinical
companies will be back in full swing, and those that have assets to bring the next
wave of APIs to IND will enjoy feast rather than famine. However, the API suppliers
who have the assets and personnel to accomplish all of the above will be in the best
position to take these forward—all the way to commercial with no tech transfers
Visit Cambridge Major Labs at www.c-mlabs.com.
INFORMEX Post Show Daily | FEBRUARY 2013 | Anaheim Convention Center Anaheim California 7
Five Minutes With…Jordi RobinsonGlobal Head, Technical Business
Development
Navin Fluorine International
What are your major concerns within your market over the next two years?
The continuing fragility of the global
economy is a major concern for us here
at NFIL & MOL. A significant part of our
business is conducted within the biotech
sector of the pharmaceutical industry and
this sector, perhaps more than any other, is
dependent upon outside funding, often from venture capitalists, for continuation
of its operations. A continued weakness in the recovery will have a profound effect
on both the amount and type of investment venture capitalists are looking to make.
By its very nature, the development of new drug candidates is a high risk endeavor.
The industry needs investors who are prepared to think long-term and are prepared
to take higher risks. Our concern is that if the recovery remains weak, investors will
look to shift their support to companies with later-phase, and thereby lower risk,
candidates. This will inevitably have an impact on the overall number of new drug
candidates coming through.
Among the challenges facing the industry, which one do you think is the most pressing—and why?
The biggest challenge facing the industry is the difficulty in bringing new drug
candidates to market. A significant reason why the “patent cliff” poses such a big
problem for the industry, is the huge expense and complex regulatory requirements
to bring new products to market. Whether through greater partnering by the global
pharma companies with complimentary organizations within the biotech/virtual
pharma sector, through a more collaborative approach by the various regulatory
bodies across the globe, or simply developing a more open and constructive
relationship with outsourcing partners; the pharmaceutical industry as a whole
needs to make it a priority to reduce the time, and thereby the cost, of bringing a
new drug candidate to market.
What should be the common goals within the industry and/or marketplace?
My belief is that within the pharmaceutical industry there should be more
collaboration and less competition. Many companies still persist in trying to
complete work in-house when there are often external providers who would be
better placed to assist. I believe that wherever a need for a particular technology
exists and a company with demonstrable expertise can be found, collaboration
should always be viewed as the most appropriate first step. This does, of course,
place great responsibility on the partnering companies to demonstrate said expertise
but, provided they can deliver what the client is looking for and provided both
parties are open and honest at the outset about what they are looking to achieve,
See 5 Minutes With…Navin Fluorine page 11
8 INFORMEX Post Show Daily | FEBRUARY 2013 | Anaheim Convention Center Anaheim California
Siegfried Shows Revenue, Profitability GrowthActive worldwide in the primary and secondary
production of drugs, the Siegfried Group has
production facilities in Switzerland, Malta, and
the U.S. It develops and manufactures active
pharmaceutical ingredients for the research-
based pharmaceutical industry, as well as the
corresponding intermediate steps and controlled
substances, and provides development and
production services for drugs in finished-dosage
forms including sterile filling.
Siegfried offers expertise in customer
development for complex oral drug delivery systems,
co-product development, manufacturing and
licensing, as well as a portfolio of finished dosage
form products. Siegfried is active in both the primary
and secondary production of drugs.
The company develops and manufactures
active pharmaceutical ingredients for the research-
based pharmaceutical industry as well as the
corresponding intermediate steps and controlled
substances, and provides development, and
production services for drugs in finished dosage
forms including sterile filling.
At the end of 2011, Siegfried, which employs
800 people, reported annual sales of CHF 328
million. Siegfried Holding AG is listed on the Swiss
Exchange (SIX: SFZN). During the first half of 2012,
the Siegfried Group maintained revenue growth
and increased profitability while progressing with
the company strategy. Net sales increased by 2.9
percent.
Drug-product development and manufacturing is
provided at the company’s Zofingen, Switzerland,
and Malta locations. The Zofingen facility is
approved by Swiss Medic/FDA regulatory
authorities, and Malta is approved by Malta
Medicines regulatory authority. Company
strengths include solid oral dosage formulation
development expertise; innovative process
optimization and improvement; expertise in a
variety of different technologies; creative life-cycle
management approaches; cGMP formulation
scale-up, clinical trial manufacturing, and
production throughout whole product
lifecycle; dedicated project management
offering transparency, flexibility, and proactive
relationships; proactive product co-development
with selected partners; and quality and regulatory
compliance.
Siegfried maintains a compliance board with
qualified senior management for global compliance
along its value chain of drug substance and drug
product.
Visit Siegfried at www.siegfried.ch/.
Chiral Technologies Expands Services in AsiaThe life science services sector is growing rapidly in Asia,
as global pharmaceutical companies outsource work in
an effort to reduce costs and move medicines to market
faster. Following this market dynamic, Chiral Technolo-
gies has expanded its capabilities for medium-to-large
scale custom separation services in China and India.
“The demand for value-added separation services in Asia
is higher than ever as more global pharmaceutical companies
outsource their drug discovery studies to this region,” said
Dieter Heckmann, CEO of Chiral Technologies. “Chiral Tech-
nologies looks forward to assisting new and current global
customers with their custom separation projects, small to
large, in order to facilitate a faster and more economical path
to clinical trials and commercial development.”
The focus of Chiral Technologies’ custom separation
services is rapid and cost-effective production of
single enantiomer compounds. The company’s global
laboratories are equipped with high performance liquid
chromatography, supercritical fluid chromatography and
simulated moving bed chromatography systems.
With the availability of a portfolio of chiral stationary
phases, Chiral Technologies provides resolutions of chiral
compounds in quantities ranging from milligrams to multi-
kilograms. Visit Chiral Technologies at www.
chiraltech.com .
INFORMEX Post Show Daily | FEBRUARY 2013 | Anaheim Convention Center Anaheim California 9
Five Minutes With…Paul N. WituschekVice President, Global Business Development
& Client Services, Development and Clinical
Services
Catalent
What are your major concerns within your market over the next two years?
As pharmaceutical and biotech
companies continue to merge and evolve, their requirements in terms of being
able to get molecules to market quickly become increasingly complex. We have
seen this lead to longer decision making times, as companies evaluate their internal
capabilities vs the option to outsource one or more stages of the development, drug
delivery, or manufacturing life-cycle.
Among the challenges facing the industry, which one do you think is the most pressing—and why?
The increase in global regulatory requirements is universally challenging
throughout the pharmaceutical and biotech sectors. With each new guidance that
is introduced, companies have to quickly “come up to speed,” be compliant, and at
the same time try not to delay timelines. Changes may require new processes, costly
equipment, and a greater depth and breadth of expertise.
What is one relevant question (and your answer) that you believe no one is addressing adequately?
Q: How can we best address regulatory requirements as we progress the
development of our biologic or biosimilar product?
A: Global manufacturers are exploring the possibility of producing biosimilars
or follow-on biologics to extend product pipelines and increase the availability of
lower cost products. As biopharmaceuticals are relatively large, complex molecules,
manufacturing changes, even relatively minor ones, may alter clinical efficacy and
ultimately the safety of the biologic product—complicating their development. In
addition to the scientific challenges, companies are grappling with understanding
the regulatory aspects and current requirements for the development of biosimilars
destined for U.S. and European markets. Companies need to work closely with their
development, manufacturing, and regulatory partners to best understand how to
progress their biosimilar product and ensure successful product registration
What are two strategies—either personal or professional—you feel important to initiate this year?
Increasingly companies are looking for a strategic outsourcing partner that
provides pharmaceutical and biotech companies with the opportunity to collaborate
on global level to provide specialist skills and knowledge from the development
phase, all the way through registration to commercialization. An initiative that we
have recently launched is the Catalent Applied Drug Delivery Institute, which aims
See 5 Minutes With…Catalent page 17
10 INFORMEX Post Show Daily | FEBRUARY 2013 | Anaheim Convention Center Anaheim California
Phenomenex Meets the Needs of Preparative HPLC with Media and Method Development SupportDemand for the production of highly pure compounds continues to grow
in a wide range of industries. Phenomenex, a leader in chromatographic
media, offers several product lines to meet the needs of analytical and
preparative applications, including pharmaceutical, API, neutraceutical
and contract manufacturing and research organizations.
Five Phenomenex brands meet various purification needs. In
addition to bulk quantities for large-scale purification, many of the
Phenomenex media are available in the company’s proprietary Axia
preparative columns. This advanced column packing and hardware
design delivers extended lifetime, increased reproducibility and
efficiencies, improved peak shapes, increased loadability and stability
under high flow rates.
The Phenomenex Lux amylose and cellulose selectors provide a
variety of complementary selectivities for chiral compound
separation under reversed phase, polar organic, normal phase
and SFC conditions. Lux is available in bulk quantities for large-scale
purification as well as in Axia hardware, for simplified chiral separation
and purification.
Luna HPLC columns, packed with ultra-pure silica, are used for the
reversed phase separation of peptides and small molecules. Luna is
scalable from microbore to preparative and purification scale. Jupiter
columns are designed for the analysis and purification of biosimilars,
proteins and pegylated peptides. The Synergi line provides an alternative
selectivity for polar compounds and the Sepra family offers silica
solutions for low pressure and flash chromatography along with
polymeric solutions for oligonucleotide purification and ion exchange
chromatography.
Method Development and Optimization Services for Large-Scale PurificationMethod development and process optimization are critical to successful
large-scale chromatographic purification. PhenoLogix is a dedicated
Phenomenex analytical support laboratory that delivers customized
expertise and solutions with fast turnaround. Customers can send their
compounds to PhenoLogix and quickly receive fully optimized method
development recommendations—including media, mobile phase
conditions, theoretical loading, and yield. PhenoLogix can also take
an existing method and re-optimize it for better yield and purity and
time and cost savings. PhenoLogix also performs contract purification
services, in amounts up to .5 kilograms. In addition to reversed phase
chromatography and small molecule separations, PhenoLogix offers free
chiral screening services.
INFORMEX Post Show Daily | FEBRUARY 2013 | Anaheim Convention Center Anaheim California 11
it is my opinion that adopting a truly
integrated approach from an early
phase is the best way to reduce time,
cost, and risk.
What are two strategies—either personal or professional—you feel important to initiate this year? Cost-cutting? Additional capital expenditure? Additional marketing investments? Team building? More emphasis on social media?
Marketing is one area where we
at NFIL & MOL will be investing more
in 2013. We are companies with
significant experience and expertise
in fluorination chemistries and have
recently made substantial capital
investments in improving and adding to
our manufacturing facilities. We now
feel we are well positioned to support
projects at any stage of development
and this is the message we will be
taking to market in 2013. Fluorine is
an essential component of many drug
candidates but fluorination is a complex
and often hazardous chemistry to
undertake. We feel that it is important
that customers are aware that we are
a company that has both the relevant
expertise to solve their problems and
the appropriate facilities to support the
full life-cycle of their project.
Social media is another area
where NFIL & MOL will be making
an investment in 2013. Although
I still believe, from a business to
business perspective, social media
is still in its infancy, I do believe it is
becoming an increasingly important
tool for businesses within the industry.
Many global brands have embraced
the technology as a way of directly
engaging with their customers, mainly
in consumer products, but outside
of the major multi-nationals, most
companies in the chemical industry
have been reticent to commit resources
to developing their ‘social presence’. As
the next generation of graduates and
future business leaders come through
the system, people who regard social
media as an essential part of daily life,
it is precisely those companies who
act now that will be positioned as the
global brands of the future.
Navin Fluorine International (NFIL) &
Manchester Organics Ltd (MOL) are
high-quality manufacturers of speciality
organic building-blocks, with strong
expertise in fluorination at all scales of
operation.
From Navin page 7
New Tosoh Fluorine Fine Chemical LaunchedTosoh F-Tech has an addition to its
product line of fluorinating agents
and building block fluorine chemicals,
(Difluoromethyl)trimethylsilane. This
reagent incorporates a Difluoromethyl
group cleanly into a molecule without
unwanted impurities normally observed
from traditional fluorination methods.
In the presence of a Lewis base, (Difluo-
romethyl)trimethylsilane reacts with
aldehydes, ketones, and imines to give
the corresponding products in good to
excellent yields under mild conditions.
Introduction of highly electronega-
tive fluorine atoms into a molecule can
lead to a number of advantages. These
include a change in lipophilicity allow-
ing passage of the molecule through
the cell membrane, increased binding at
the active site, and increased bioavail-
ability as fluorinated molecules are
harder to metabolize.
Recently, pharmaceutical and
agrochemical companies have investigated
the substitution of the Trifluoromethyl
group with a Difluoromethyl group. Visit
Tosoh at www.tosohusa.com.
12 INFORMEX Post Show Daily | FEBRUARY 2013 | Anaheim Convention Center Anaheim California
Rieke Metals’ Expansion Provides Greater Depth in Product Availability For 21 years, Rieke Metals
has provided novel reagents
for drug discovery and material
science. The latest expansion
to its facility in Lincoln, Neb.,
allows for bulk quantities of
unique organozinc reagents
and specialized Grignard
reagents.
Founded in 1991, the
company offers a range of
technology based on highly
reactive metals, including
magnesium, zinc and
manganese. The exceptional
reactivity of these metals
allows the preparation of
novel organometallic reagents,
many displaying unusual
functionality.
Rieke zinc reacts directly
with alkyl, aryl, and vinyl halides and tolerates a broad range of functional groups,
such as chlorides, nitriles, esters, amides, ethers, sulfides and ketones. Also of
significance is that aryl halides show no scrambling of position when ortho-, meta-
or para-substituted substrates are used.
Rieke magnesium allows
the preparation of many
Grignard reagents that are
not possible using standard
magnesium methods. It can
allow Grignard formation at
lower temperatures, avoiding
decomposition or unwanted
additions. The advantages of
low-temperature Grignard
preparation include many
benzylic systems, which tend to
yield homocoupled products at
room temperature or above.
In addition to
organometallic compounds, the
facility proudly manufactures
more than 10,000 research
compounds and more than
350 thousand molecules under
research contract. Among these
fine organic chemicals are a large number of heterocyclic compounds.
Rieke Metals holds many patents in the area of semiconducting polymers and
offers regioregular and regiorandom P3HT in gram to kilogram quantities.
Visit Rieke Metals at www.riekemetals.com.
INFORMEX Post Show Daily | FEBRUARY 2013 | Anaheim Convention Center Anaheim California 13
Five Minutes With…John RiceExecutive Director
The Chemical Educational Foundation
Among the challenges that industry faces, which do you think are the most pressing?
A huge challenge to the industry is educating people, specifically youth, to under-
stand what the chemical industry achieves for them. Where would you be without
science? You definitely wouldn’t be down the street at Disneyland! Science is behind all
of the “magic” that Disney creates on a daily basis in the form of engineering new park
rides, creating animated movies—even down to food they serve in concession stands.
Do the millions of people that visit the park annually have even the slightest clue that sci-
ence, specifically technical innovation and physics, is the reason that favorite amusement
rides like Splash Mountain exist?
If you’re reading this, you most likely work for a chemical company and are well-versed
in the value that science and the industries that support it provide to man-kind on a daily
basis. The challenge is making sure that your stakeholders and community members are
also aware of these advantages. Ignoring this need for education creates a lack of under-
standing of the benefits that industry provides to the general public’s everyday lives. What
people don’t understand, they tend to fear, and that can result in overzealous regulation
that impacts industry as a whole, weakening the economy from top to bottom.
What should be the common goals within the industry and/or marketplace?
A common goal within industry should be educating constituents about the
vast benefits of science. It is industry’s responsibility to itself and society to take a
leading role in the advancement of science education initiatives. This direct involve-
ment will help eliminate the negative stigmas placed on the chemical industry and
create future generations of well-informed citizens. In any production process, what
we put in is central to the end result. For industry as a whole, getting involved in
efforts to improve the US education system should not be considered “community
outreach” or “philanthropy” but more as activities that are central to your “right to
do business” argument.
Many chemical companies are already involved. Industry management programs
such as the National Association of Chemical Distributors’ Responsible Distribution, the
American Chemistry Council’s Responsible Care, and, of course. SOCMA’s ChemStewards
program, are asking their member companies to make a commitment to improving
science education opportunities for our youth by placing greater emphasis on supporting
science, technology, engineering, and math (STEM) initiatives. Increasing these efforts and
the number of engaged companies should be the common goal among all industry.
CEF is a non-profit organization that works with the chemical industry to enhance
science education for students and educators in grades K-8. By emphasizing the
central role of chemistry in all the sciences and in oeveryday lives, CEF strives
to inspire future leaders in pursuing science-related careers and to improve the
overall understanding of, participation in, and appreciation of chemistry and
chemicals.
14 INFORMEX Post Show Daily | FEBRUARY 2013 | Anaheim Convention Center Anaheim California
Industrial Chromatography: Novasep Continues to Gain Momentum
The growing demand for
advanced purification on the
pharmaceutical market recently
has led Novasep to invest $40
million in a chromatography plant
at its Mourenx, France, site. This
new plant, designed by Novasep’s
in-house engineering team, will
include Varicol systems with 1,200
mm diameter columns operating at up to 70 bar.
Earlier last year, Novasep announced a $4 million investment in its Safebridge-
certified facility in Le Mans, France. This plant is dedicated to the production of
highly potent APIs from a few grams per day to tens of kilograms per week. The
new production facility will include large-scale industrial HPLC equipment and
increased capacities to the site’s current cGMP purification suites in confined
environments (OEL down to 0.03 µg.m-3.8h-1).
These investments in Le Mans and Mourenx, France, add capabilities to Novasep’s
worldwide purification platform with additional facilities in Shanghaï, China; Boothwyn,
Pa.; Pompey, France; and Chasse-sur-Rhône, France. This platform operates proprietary
preparative chromatography systems and relies on experienced process development and
engineering teams. Benefitting from a 15-year proven track record, it provides process
development as well as pilot and commercial scale manufacturing services.
Novasep provides its customers with insourcing or outsourcing solutions for the
purification of fine chemicals and active pharmaceutical ingredients at large scale.
Visit Novasep at www.novasep.com.
CU Chemie Uetikon Reactor on Task with Successful Production CampaignsCU Chemie Uetikon’s two new Cryogenic Reactor at its cGMP Plant in Lahr, Germany
has undergone first production campaigns successfully. The 100-liter (26 gallon) and
2,500-liter (660 gallon) reactors with the capability of reaching -80 °C -110 F°F) are ready
for additional new projects. These low temperature reaction vessels have completed CU
Chemie Uetikon’s investment at its cGMP Plant MPA P3 and its pilot plant
The company has finished the expansion of its multipurpose cGMP production
unit (MPA P3) and pilot plant in Lahr, Germany, and is now going full steam ahead.
Additional capacity for production of high value, late stage intermediates, and
pharmaceutical active ingredients is now available to small, emerging as well as
large pharmaceutical companies.
The cGMP plant has four independent operating production lines at its disposal,
enabling the customers to obtain premium quality products, which will satisfy the
requirements of the FDA and other regulatory agencies. Its total reactor capacity is
91.5 m3 (24,200 Gallons).
From pre-clinical through commercialization, CU Chemie Uetikon enables
customers to bring their products to market in the most efficient timeframe
possible. The Lahr team is particularly proud of its record in numerous FDA
inspections carried out since 1987. The last inspection in 2010 was passed, just like
the one before, without any adverse comments or forms 483 complaints.
Chemie Uetikon has particular expertise in high-pressure reactions (up to 100
bar/1,400 psi), hydrogenation, Grignard reactions, Carbonylation techniques, and a
complete range of small to large-scale technologies for chemical synthesis.
Visit Chemie Uetikon at www.uetikon.com.
INFORMEX Post Show Daily | FEBRUARY 2013 | Anaheim Convention Center Anaheim California 15
Euticals offers more than 200 active in-
gredients for different therapeutic areas
and about 600 advanced intermediates
via economically competitive processes
from kilograms to metric tons.
Of the 11 sites located in Europe
and the U.S. where its products and
services are offered, 10 of the sites
operate under cGMP rules, with
eight being FDA approved and one in
Springfield, MO, with a DEA permit for
controlled substances.
The challenges and rising costs of
doing business in the East (India and
China), compounded by the new EU
and USA laws will affect API sourcing
decisions. Euticals’ business model is
revolving around manufacturing in
the Western markets, such as Italy,
France, Germany, United Kingdom and
the U.S., where it has an established
manufacturing footprint.
As an increasing number of
products losing patent protection over
the next decade will be specialized,
Euticals is focusing on innovative and
cost effective processes, as well as
niche technologies for sustainable
sales growth in North America and
Emerging-pharma markets.
In API manufacturing, oncology APIs
are core product lines. The Italian sites
at Lodi and Varese produce HPAPIs and
cytotoxics from grams to commercial
scale. Both of these sites completed
capacity expansions in 2012. The
company also offers injectable dosage
forms for oncology from a Swiss joint-
venture site.
Euticals offers sterile aseptic API
facilities in France to accommodate
Band 3 and 4 compounds. It
has capacity for high potency
fermentation at Rozzano Italy
for immunosuppressants and
neuromuscular blocking agents, while
the Origgio, Italy, site offers the gamut
of APIs including tetracyclines. Euticals
also is a strong player in supporting
pharma generic customers for
paragraph IV and 505-2b filings with
innovative technologies.
The contract manufacturer has a
combination of a broad technological
base, particularly in the fields of
organometallic chemistry, heterocyclic
chemistry, enzymatic chemistry,
fermentation, and experience in
scale-up to commercial scale. With
commercial experience in transition
metal coupling reactions with boronic
acids and related chemistries, it makes
more than 150 boronic acids from
kilograms to several hundred metric
tons at sites in Germany, France, Italy,
and the U.S. These boronic acids range
from simple to highly functionalized,
and include aliphatic, aromatic, and
heterocyclic compounds. Visit Euticals
at www.euticals.com.
Euticals’ Products Offered from 11 Sites in Europe, U .S .
Albemarle Continues Expansion in PennsylvaniaAlbemarle, a global developer,
manufacturer and marketer of highly
engineered specialty chemicals and
services, announced today that its Fine
Chemistry Services (FCS) business has
approved and begun construction on
another expansion of its Tyrone, PA
custom manufacturing facility.
“This $30 million expansion
adds new capacity to the site for
custom manufacturing projects, but
more importantly, will improve the
infrastructure to allow for future
See Albemarle page 18
16 INFORMEX Post Show Daily | FEBRUARY 2013 | Anaheim Convention Center Anaheim California
Digital Specialty Earns Ligands LicenseDigital Specialty Chemicals—a manufacturer
of high quality organophosphorus and
organometallic chemicals known for its agility
to innovate and meet rigid timelines—has been
granted a worldwide license for the Buchwald
organophosphine ligands from M.I.T. The
license covers composition of matter and the
use of the ligands in metal-catalyzed processes.
With DSC’s interest in addressing requirements
of global pharmaceutical, specialty chemical
and semiconductor markets for efficient and
effective technologies, the license will give DSC’s
customers access to proven superior tools for
planned process chemistry and engineering milestones.
The Buchwald ligands, such as JohnPhos, BrettPhos, SPhos and XPhos, have
been utilized in a broad range of palladium-catalyzed coupling reactions, including
Heck, Suzuki, Buchwald-Hartwig, Sonogashira and alpha arylations. The Buchwald
family of ligands allow for coupling of inexpensive aryl chlorides, in addition to
the more typical aryl bromides, in the preparation of C-C, C-N, and C-O bonds.
Generally, the active catalyst is generated in-situ from the ligand and a palladium
species.
“The addition of the Buchwald ligands to our existing range of chiral and
achiral phosphine ligands broadens the solutions we can offer to our customers
for coupling chemistry,” states Christine Harnett, VP of business development
pharma. “These products are an excellent fit for DSC with our core competency in
organophosphorus chemistry and our expertise in scale-up of synthetic processes.”
Visit Digital Specialty Chemicals at www.digitalchem.com.
Christine Harnett
RightAnswer .com Doubles EHS Data Sources, Announces Mobile InterfaceRightAnswer.com, headquartered in Midland, MI, has seen significant growth
in the last 12 months. Recognized by EHS specialists worldwide as a reliable
source for current chemical, MSDS, reproductive risk, and regulatory compliance
information, RightAnswer’s ChemKnowledge and RegsKnowledge Systems provide
comprehensive information from proprietary and licensed databases.
“In 2012, we doubled our data sources so our clients have access to even more
in-depth chemical data in an integrated combination that they won’t find anywhere
else,” said Glen Markham, who manages corporate business development for
RightAnswer. “This includes exclusive, proprietary content. Also, the information is
continuously updated from trusted sources and mastered to provide our users with
an unmatched, single-search simplicity.”
RightAnswer says it is committed to providing customers with the knowledge
to help: meet EHS requirements; prepare for chemical use and approvals; make
emergency response evaluations; assess toxicology risks; implement regulatory
compliance; author MSDSs, labels, and other documents; and optimize product
stewardship management.
Another soon-to-be launched innovation is the OnHand mobile interface from
RightAnswer, being released this month.
“All of the integrated data and functionality of our OnLine Application is
now optimized for smartphones and tablets with RightAnswer’s new OnHand
mobile interface,” said Markham. “This new interface supports easy access to
RightAnswer’s Knowledge Solutions in the office or on the go.”
For more information, visit www.RightAnswer.com.
INFORMEX Post Show Daily | FEBRUARY 2013 | Anaheim Convention Center Anaheim California 17
to promote innovation, knowledge
sharing and collaboration between
industry leaders, academic experts,
customers and regulators, to enhance
understanding of available, emerging,
and future drug delivery technologies,
while improving patient care. The
institute will develop programs
that facilitate mutually beneficial
collaborations, increase communication,
and shed light on key regulatory
issues affecting drug developers and
researchers.
Catalent Pharma Solutions is a global
leader in development solutions and
advanced drug delivery technologies,
providing worldwide clinical and
commercial supply capabilities for
drugs, biologics, and consumer health
products.
From Catalent page 9
ZaCH Brings Innovation Out of TraditionZaCh is a fine chemicals company
dedicated to providing its customers
with fast, cost-effective, quality
custom synthesis services, APIs, and
intermediates—offers extensive process
development support.
With more than 350 patents
covering chemical processes and
intermediates and a sustained strategy
of developing, implementing and
protecting technological innovation,
its research teams develop and apply
new and cost-effective processes for
the production of active pharmaceutical
ingredients (APIs) and advanced
intermediates.
Its worldwide presence has grown
to two cGMP production facilities—in
Lonigo, Italy, and Avrillè, France. In
addition to manufacturing capability,
each facility contains dedicated R&D
and commercial activities for custom
synthesis and generic API production.
The FDA-inspected facilities are
compliant with national/international
regulations.
Visit ZaCh Systems at www.
zachsystem.com.
18 INFORMEX Post Show Daily | FEBRUARY 2013 | Anaheim Convention Center Anaheim California
incremental and low-cost expansions as we gain new projects from customers. This
rapid response and flexibility are hallmarks of the Tyrone operating culture,” said
Randy Andrews, Tyrone site manager.
“We are pleased once again to expand the Tyrone site to serve the growing product
needs of our customers. This expansion comes shortly after our earlier expansion that
began operation in November 2012 and will fuel the continued growth of FCS’s custom
manufacturing business. We are anxious to take advantage of the eventual 40% increase
in reactor capacity. The first increment of new capacity will be operational late in the first
quarter of 2014,” said David DeCuir, FCS Business Director.
About Albemarle Albemarle Corporation, headquartered in Baton Rouge,
Louisiana, is a leading global developer, manufacturer, and marketer of highly-engineered
specialty chemicals for consumer electronics, petroleum refining, utilities, packaging, con-
struction, automotive/transportation, pharmaceuticals, crop protection, food-safety and
custom chemistry services. The Company is committed to global sustainability and is ad-
vancing its eco-practices and solutions in its three business segments, Polymer Solutions,
Catalysts and Fine Chemistry. Corporate Responsibility Magazine selected Albemarle to its
prestigious “100 Best Corporate Citizens” list for 2010 and 2011.
Albemarle employs approximately 4,000 people and serves customers in
approximately 100 countries. Albemarle regularly posts information to www.
albemarle.com, including notification of events, news, financial performance,
investor presentations and webcasts, Regulation G reconciliations, SEC filings, and
other information regarding the Company, its businesses and the markets we serve.
Visit Albemarle’s FCS division at www.albemarle.com/fcs.
From Albemarle page 15
explained that Rx-360’s mission is to “educate—but not lobby” in the process of
protecting patient safety.
The organization shares information and develops processes related to the integrity of
the healthcare supply chain and the quality of materials within the supply chain.
The four-year-old Rx-360 aims to increase its membership this year by 20 percent
in order to have “eyes and ears on the ground” all over the world to understand
regulatory requirements and keep manufacturers, suppliers, and observers engaged
with one another.
Panelists agreed that the cumbersome and disparate official tracking forms are
a particularly thorny issue. “We’re a small piece of some of our suppliers’ business,
but they need to acknowledge our requirements,” said David McCarthy, senior
director of worldwide procurement of Pfizer. “They’re not eager to come up with
a separate quality agreement for our situation, but now Rx-360 has a standardized
agreement on its website (www.rx360.org). With a standard template, nobody in
this situation has to reinvent the wheel.”
Auditing is critical, and Kim Cauchy, VP of global sourcing at Mylan, warned that
pharmaceutical companies must be vigilant to the extent that they should “audit
suppliers and audit suppliers’ auditing programs.”
McCarthy emphasized that pharmaceutical company scientists should engage
more in supply chain auditing, while Tom Beil, VP of quality and regulatory affairs at
Sigma/Alrich/SAFC, advocated that suppliers be educated “at the molecular level.”
Keeping up with regulatory requirements was another concern. Tony
Weiderhold, consultant for development and commercial API sourcing at Eli Lilly and
Co., explained, “We need to weigh security against transparency and understand
why regulations are being developed.”
Another critical issue revolves around supply chain security, which is often
subjected to political challenges. Beil suggested developing a long-term strategy
for monitoring procedures instead of developing one case-by-case with suppliers.
William Reis, VP of global strategic sourcing at Amgen, opined that such situations
“reinforce the importance of Rx-360 to share information quickly and put out best
practices.”
“Rx-360 is about coming together to solve problems,” Watson concluded.
From Rx-360 page 1
There are two kinds of intangibles. Off-balance-sheet assets, which exist now,
include customer lists, patents, brand names, software, and tooling. Goodwill
is a function of the company’s future potential. “It’s important to show growth
potential,” Oppenheimer added.
Oppenheimer method to evaluate a business starts with the organizational
structure and a chart that illustrates that the business is a going concern
that will continue—even if the owner is present. The financial statements,
adjusting expenses such as travel and real estate for profitability, are the next
part of the equation.
The marketing/marketing research section is the most telling, because it
substantiates the company’s future potential. The final evaluation comprises tthe
balance sheet equity and the goodwill and projects where the company will be in
five years.
The evaluation package can be used as a prospectus or give the seller ideas
to add value to the business. Oppenheimer uses a targeted approach to find
buyers, sends out the package, and then gets legal experts to draft the purchase
agreement.
“Go through a defined exit plan instead of spinning wheels and not getting the
right price,” Oppenheimer advised.
Neal McCarthy, managing director of Fairmount Partners, which provides
financial advisory services to support the sale of all types of businesses, including
both family owned businesses, partnerships, private equity sponsored businesses
and corporate divestitures, targeted his talk to pharmaceutical executives who are
considering the sale of their businesses.
Typically, Fairmount’s clients have built value by first establishing strong positions
in their market, and are looking for a way to maximize shareholder value for the
long-term, whether it is through an acquisition, a capital raise, or a sale of the
company.
The company’s understanding of the value creation process at each stage of its
development, combined with its transactional knowledge, enables Fairmount to
provide timely advice on strategy, valuation, transaction structure, and relevant
prospects.
Knowing the right time to sell a business, whether to sell it to a financial buyer
or an industry buyer, and prepare for a transaction to achieve a smooth transition
are key elements, McCarthy said.
Planning ahead—by as much as five years—is the key to a successful transaction,
both experts agreed.
From To Sell or Not page 1
INFORMEX Post Show Daily | FEBRUARY 2013 | Anaheim Convention Center Anaheim California 19
C&EN’s Wrap Party: A Toast to InformexUSA 2013
20 INFORMEX Post Show Daily | FEBRUARY 2013 | Anaheim Convention Center Anaheim California
Showcase Snap Shots
Scott A. Miller, head, special projects, Carbogen Amcis
Herve Limouzin, sales director, Pierre Fabre
Felix Chen, sales director, global operations, CAC Group
Hugh McManus, director, business development, Dottikon ES
Doug Cochran, VP, business development, Optima Chemical
Sandra Moro, deputy director, business development USA,
Helsinn
John Brice, senior director, business development,
Asymchem John Michnick, associate director, West Coast sales, Cambrex
Wayne Nowicki, director, business development,
Regis TechnologiesJoseph D’Antuono, account
director, North America, Evonik
Showcase attendees
INFORMEX Post Show Daily | FEBRUARY 2013 | Anaheim Convention Center Anaheim California 21
A d v e r t i s e r s I n d e xAMPAC Fine Chemicals, Booth 2257, www.ampacfinechemicals.com . . . . . 2
Ash Stevens, Inc., Booth 1552, www.ashstevens.com . . . . . . . . . . . . . . Cover
BioVectra Inc., Booth 2156, www.biovectra.com . . . . . . . . . . . . . . . . . . . . . 6
Cambridge Major Laboratories, Inc., Booth 2225, www.c-mlabs.com . . . 15
C&EN, Booth 2447, cen.acs.org . . . . . . . . . . . . . . . . . . . . . . . . . . . 13, 14, 16
Chemtura Corp., Booth1548, www.chemtura.com . . . . . . . . . . . . . . . . . . 6
DFI Pharma, Booth 1545, www.dfipharma.com . . . . . . . . . . . . . . . . . . . . . . 7
Evonik, Booth 1238, www.evonik.com/pharma . . . . . . . . . . . . . . . . . . . . . 23
Fabbrica Italiana Sintetici SpA, Booth 2049, fisvi.com . . . . . . . . . . . . . . . . 9
Federal Equipment Co., Booth 2030, www.fedequip.com . . . . . . . . . . . . 13
Helsinn Advanced Synthesis S.A., Booth 1809, www.helsinn.com . . . . . . . 8
J-Star, Booth 1343, www.jstar-research.com . . . . . . . . . . . . . . . . . . . . . . . 10
LIST USA Inc., Booth 2419, www.list.us . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
Nova Molecular Technologies, Inc., Booth 1442, www.novamolecular.com . 7
Oakwood Products, Inc., Booth 1109, www.oakwoodchemical.com . . . . 21
Organic Technologies, Booth 1247, www.organictech.com . . . . . . . . . . . 10
PCI Synthesis.com, Booth 1059, www.pcisynthesis.com . . . . . . . . . . . . . . 12
PharmaCore, Inc., Booth 1303, www.pharmacore.com . . . . . . . . . . . . . . . 11
Ricerca Biosciences, Booth 2060, www.ricerca.com . . . . . . . . . . . . . . . . . 17
Siegfried USA, Inc., Booth 1101, www.siegfried.ch . . . . . . . . . . . . . . . . . . 12
Umicore AG & Co. KG, Booth 1131, www.umicore.com . . . . . . . . . . . . . . . 5
Zach Stystem S.P.A., Booth1701, www.zachsystem.com . . . . . . . . . . . . . . 14
Pope Scientific’s Distillation Contract Services For Heat Sensitive MaterialsPope Scientific specializes in high-
vacuum distillation toll processing
services for heat-sensitive materials.
Operations include molecular (short-path)
distillation, evaporation, concentration,
devolitilization, deodorization,
and hybrid wiped-film/fractional
column distillation. Typical examples
include separation and purification
of pharmaceuticals, intermediates,
biomaterials, vitamins, nutraceuticals,
cosmetics, edible and essential oils, esters,
fine chemicals, solvents, foods, flavors,
fragrances, polymers, extracts, waxes,
monoglycerides, and silicones.
New developments in “hybrid
distillation” allow fractional separations
of materials close in boiling point, even
when heat sensitive.
The new facility is licensed
for food processing, certified for
Kosher processing, and capable of
cGMP operation. Feed lots from liters to truckloads are handled with
rapid turnaround, minimizing client’s risk, time-to-market and development
costs. Professional experienced staff assures quality processing, proper
documentation and confidentiality.
In addition, feasibility testing services
are offered, utilizing Pope’s two-inch
and larger wiped film stills, set up in
configurations appropriate for the
process. GC and other instruments can
be utilized for in-process analyses as
required. Confidential reports with all
data are presented.
Pilot plant processing is offered for
scale-up rate studies, process strategy
development, production of small
pail and drum lots for client sample
distribution, and practical finished
product testing.
Combined lab and pilot scale studies
can lead to a comprehensive set of
knowledge enabling preparation for large
scale contract processing campaigns as
well as specification and design of turnkey
distillation equipment for manufacturing
and sale to clients. In many cases, the overall
resulting system is comprised of multiple stages of various units, including molecular stills,
evaporators, hybrid fractional stills and/or passive degasser units.
Visit Pope Scientific at www.popeinc.com.
22 INFORMEX Post Show Daily | FEBRUARY 2013 | Anaheim Convention Center Anaheim California
Exhibitors Light Up Convention